FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res
After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy
More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S. regulator for its first approved drug.
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Ryoncil Receives FDA Approval for Children With GVHD
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in the U.S.
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.
Mesoblast awarded FDA approval for Ryoncil
Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making it the first mesenchymal stromal cell (MSC) therapy to be approved in the United States for any indication.
Mesoblast’s Ryoncil: A Breakthrough in Pediatric Therapy
Mesoblast Limited (AU:MSB) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked
Mesoblast has received FDA approval for its drug Ryoncil
Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration approved its drug Ryoncil for use in infants and children.
Mesoblast ADRs Rise 22%, FDA Approves Ryoncil for Pediatric Patients -- Update
The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
FDA Approval Boosts Mesoblast’s Market Position
Mesoblast Limited (AU:MSB) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked
Benzinga.com2d
What's Going On With Mesoblast Shares Thursday?
Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute ...
Hosted on MSN2d
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech ...